$TGTX - On our trading list with news today or analyst comments with our opinion & trade ideas. JPMorgan initiates coverage of TG Therapeutics with an Overweight rating and $38 price target.TG Therapeutics initiated with an Overweight at JPMorganJPMorgan analyst Eric Joseph initiated coverage of TG Therapeutics with an Overweight rating and $38 price target. The company's lead candidate umbralisib, either alone or combined with propriety CD20 antibody ublituximab, represents differentiated therapy in the hematologic B-cell malignancies space, Joseph tells investors in a research note. The analyst sees "compelling" commercial potential in the indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia populations.Our Take: Our top pick currently. Going strong! $TGTX, TG Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .